Last updated: February 22, 2026
What is the Product?
NDC 51407-0738 corresponds to Bridion (sugammadex), a drug used to reverse neuromuscular blockade induced by rocuronium or vecuronium during anesthesia. Bridion is marketed by Merck and approved in multiple countries, including the United States.
Market Size Overview
Supply and demand factors influence Bridion’s market size, driven primarily by anesthesia practices, surgical volumes, and preferences for neuromuscular blockade reversal agents.
Global Market Context
- Global anesthetic reversal agents market size was valued at approximately USD 3.5 billion in 2021.
- The Bridion segment accounted for an estimated 55% share in the neuromuscular blockade reversal niche in 2022, valued at around USD 1.9 billion.
- Compound annual growth rate (CAGR) is roughly 5% from 2022 to 2027.
U.S. Market Specifics
- U.S. anesthesia market estimated at USD 1.2 billion in 2022.
- Bridion is the leading reversal agent, with a market share surpassing 60%.
- Annual sales in the U.S. approached USD 700 million during 2022–23.
Key Competitors
- Neostigmine (less expensive, less preferred for rapid reversal)
- Rocuronium (used directly as in some protocols)
- Other agents with limited market penetration
Regulatory and Insurance Factors
- Bridion is FDA-approved (2015) with broad insurance coverage.
- Cost considerations influence adoption, favoring shorter anesthesia times and improved outcomes.
Pricing Dynamics
Current Retail Price
- Average wholesale price (AWP): around USD 133 per 200 mg vial.
- Average sales price (ASP): approximately USD 125 per vial.
- Reimbursement levels generally range from USD 135 to USD 150 per vial depending on provider contracts and payers.
Pricing Trends
- Prices have remained stable since launch, with minor variations due to inflation and regional pricing policies.
- Hospital procurement discounts decrease net prices by approximately 15–20%.
Pricing in Different Markets
| Region |
Approximate Price (per vial) |
Notes |
| United States |
USD 125–150 |
Based on ASP; varies by contract |
| European Union |
EUR 120–140 (USD 130–150) |
Similar to U.S. prices, slightly higher |
| Asia-Pacific |
USD 80–110 |
Lower due to market dynamics and pricing regulations |
Future Price Projections
Based on current trends, regulatory landscape, competitive pressures, and inflation:
| Year |
Projected Price Range (per vial) |
Factors Influencing Price |
| 2024 |
USD 125–155 |
Stable, minor inflation |
| 2025 |
USD 125–160 |
Potential price adjustments due to healthcare policy changes |
| 2026 |
USD 125–165 |
Market stabilization, innovation in anesthesia practices |
| 2027 |
USD 125–170 |
Slight upward trend due to inflation and increased hospital budgets |
Market Drivers and Risks
Drivers
- Increasing volume of surgical procedures requiring neuromuscular reversal
- Adoption of sugammadex over traditional agents for safety and speed
- Growing healthcare expenditure on perioperative safety
Risks
- Price competition from generic sugammadex products and other reversal agents
- Regulatory changes affecting pricing policies
- Healthcare policy shifts impacting reimbursement
Licensing and Patent Landscape
- Bridion's primary patent expired, with some secondary patents still active until 2027–2030.
- Entry of generic versions could pressure prices downward by 2025–2026.
Key Takeaways
- Bridion is the dominant neuromuscular reversal agent, with a surveyed market value around USD 1.9 billion globally.
- Market growth sustains at approximately 5% annually, driven by surgical volume increases.
- Current prices are stable, averaging USD 125–150 per vial in the U.S., with slight upward pressure projected through 2027.
- Price competition from generics is anticipated to begin influencing the market from 2025 onward.
- Access and reimbursement policies significantly affect net revenue potential.
FAQs
-
What factors could cause Bridion's price to decline earlier than projected?
Introduction of generic alternatives, changes in patent protections, and shifts in reimbursement policies.
-
How does Bridion’s market share compare globally?
It holds about 55–60% of the neuromuscular reversal market globally but varies by region.
-
Are there regulatory barriers to generic versions?
Existing patents and secondary patent protections delay generic entry until approximately 2027–2030.
-
What is the potential impact of new anesthesia reversal agents?
Competition could reduce prices and market share for Bridion if new agents demonstrate comparable efficacy and cost advantages.
-
How do hospital procurement practices influence pricing?
Contract negotiations often lower net prices by 15–20%, impacting overall revenue.
References
[1] Statista. (2023). Global anesthetic reversal agents market size.
[2] EvaluatePharma. (2022). Sugammadex market analysis.
[3] U.S. Food and Drug Administration. (2015). Bridion approval documentation.
[4] IQVIA. (2022). U.S. hospital drug purchasing and pricing data.
[5] European Medicines Agency. (2023). European pricing and reimbursement overview.
